Particularly like the one on one meetings with several of our BOD members present.
In my negotiations surrounding mergers and partnerships, one on one was the precursor to the path forward to funding arrangements, several US based BOD will be present to make that happen. This will have given the US based new board members to prepare such talks for about 3 to 4 months, the usual period given for such preparations, timing with tox data coming online within weeks and preparing clinical studies for which vast amount of money is needed.
They have deepened engagement with prominent healthcare industry investors along with a wide range of potential business development partners, as shared in July, culminating in Sahm Nasseri, U.S. Chief Executive Officer of PYC, will present a corporate overview on Tuesday, September 21, 2021 at 4:35 p.m ET. Members of PYC’s management team will also participate in one-on-one meetings with U.S biotech and life science investors.
We are moving up the ladder towards a funding arrangement similar to Eli Ely and ProQR as shared by hottod previously, in my opinion, two fold existing of advance payments, equity at a premium ( explaining the parked share price at 15 cents ) and possibly an IP and ownership deal similarly to the deal with LEI for our first ocular programs.
BOD is going through the motions and signs have been ample for Australian investors to wake up to the upcoming rerate.
The usual reaction on the ASX is react once the cat is out of the bag, only a handful of investors position early.
all IMo
PYC Price at posting:
14.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)